Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 195

Results For "NSE"

2388 News Found

CanSinoBIO's Convidecia approved as heterologous booster in China
News | February 21, 2022

CanSinoBIO's Convidecia approved as heterologous booster in China

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants


Sputnik Light gets a boost as China changes rules on boosters
News | February 21, 2022

Sputnik Light gets a boost as China changes rules on boosters

Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters


Gujarat unveils ambitious Biotech Policy 2022-27
Policy | February 21, 2022

Gujarat unveils ambitious Biotech Policy 2022-27

According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories


Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes
Healthcare | February 21, 2022

Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes

According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic


Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus
News | February 21, 2022

Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus

CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Indian pharma industry needs a winning partnership
News | February 19, 2022

Indian pharma industry needs a winning partnership

The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines


Covid-19 fuels innovative PCR-based detection methods
Medical Device | February 19, 2022

Covid-19 fuels innovative PCR-based detection methods

According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years


EC approves Tepmetko to treat non-small cell lung cancer
Drug Approval | February 19, 2022

EC approves Tepmetko to treat non-small cell lung cancer

Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment